Applied BioCode Corporation reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 105.75 million compared to TWD 107.77 million a year ago. Net loss was TWD 43.73 million compared to TWD 44.11 million a year ago. Basic loss per share from continuing operations was TWD 0.53 compared to TWD 0.54 a year ago. Diluted loss per share from continuing operations was TWD 0.53 compared to TWD 0.54 a year ago.
For the nine months, sales was TWD 266.94 million compared to TWD 269.57 million a year ago. Net loss was TWD 155.62 million compared to TWD 149.52 million a year ago. Basic loss per share from continuing operations was TWD 1.9 compared to TWD 1.83 a year ago. Diluted loss per share from continuing operations was TWD 1.9 compared to TWD 1.83 a year ago.